Please ensure Javascript is enabled for purposes of website accessibility

A Product Safety Issue Crashed Elanco's Stock. Is This a Buying Opportunity?

By Luis Sanchez CFA – Updated Apr 27, 2021 at 1:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Elanco's share price has come under pressure amid new concerns over a key product.

Elanco Animal Health's (ELAN -1.98%) stock caught fire recently, after more bad news arrived for one of its flagship products. Elanco is a pet pharmaceutical company that added Seresto to its portfolio after purchasing Bayer Animal Group (a subsidiary of Bayer) last year.

Seresto is a tick and flea collar designed to work on both cats and dogs. Unfortunately, the collar has built up a record as a potentially dangerous product for pets and humans alike. These recent findings have been a black eye for the company, and pose several risks including that the products could be pulled from the market or legal action from a civil suit. Given the risks, should investors buy the stock or wait on the sideline?

a family sitting on a couch with three dogs

Image source: Getty Images.

A brief backstory

Bayer Animal Group initially developed Seresto, which received Environmental Protection Agency (EPA) approval in 2012. Elanco was able to add Seresto to its portfolio via its gargantuan $7.6 billion acquisition of Bayer Animal Group.

The collar is one of Elanco's top 10 best-selling products and brought in revenue of $84 million last year. Notably, Elanco only began selling Seresto after the acquisition completed in August. Seresto has been a cash cow since it was released, but the situation has quickly changed for the product.

Problems with Seresto

Data has been brought to light showing the product's concerning track record. Since Seresto was introduced, the EPA has received reports of over 75,000 total pet injuries and just under 1,700 pet fatalities.

To give this number some context, the next most dangerous pet collar pesticide, TCVP, had ties to 4,576 injuries and 363 deaths from 1992 to 2008, much lower numbers than those attributed to Seresto. According to the Natural Resources Defense Council (NRDC), the EPA's study shows that TCVP's toxic residue can expose children to up to 1,000 times above the EPA's safety level.

Because of these health issues, both TCVP and Seresto are being taken to court. Two pet owners have recently filed a class action lawsuit against Elanco, and more are likely to follow. These lawsuits come on the back of a congressional subcommittee request that Elanco voluntarily recall the flea and tick collars.

Seresto is still on the market as of April 26, but it wouldn't be surprising if the company succumbs to pressure to stop selling it. If the product is as harmful to pets as some claim, the company could face legal action in the form of a civil suit or other legal ramifications. Furthermore, if customers associate this harmful product with Elanco, the company is also risking long-term damage to its reputation.

Should investors buy the dip?

Elanco's stock is down about 10% since the congressional subcommittee asked for the company to recall its product.

ELAN Chart

ELAN data by YCharts

The product safety issues look pretty serious for Seresto, but the product accounts for less than 3% of the company's total revenue. A 10% hit for a relatively small portion of revenue may be an overreaction by the market. Outside of Seresto, Elanco makes its money by selling other pharmaceutical products to the pet animal and livestock animal markets. The company has a large business selling vaccines to farmers to help protect their herds from various ailments.

On the other hand, investors looking to enter the pet pharmaceuticals space may be better off letting the dust settle on Elanco and Seresto. Other companies in the industry, including Zoetis and Idexx Labs, offer broader portfolios of products and exposure to other attractive areas of animal health without the drama of a product recall fight.

Luis Sanchez CFA owns shares of Idexx Laboratories and Zoetis. The Motley Fool owns shares of and recommends Idexx Laboratories and Zoetis. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Elanco Animal Health Incorporated Stock Quote
Elanco Animal Health Incorporated
ELAN
$12.41 (-1.98%) $0.25
Bayer Stock Quote
Bayer
BAYR.Y
$11.56 (-1.36%) $0.16
Zoetis Inc. Stock Quote
Zoetis Inc.
ZTS
$148.29 (-1.76%) $-2.66
IDEXX Laboratories, Inc. Stock Quote
IDEXX Laboratories, Inc.
IDXX
$325.80 (-1.81%) $-6.01
Bayer Stock Quote
Bayer
BAYN
$47.48 (0.47%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.